New drug evaluation. The experience of the Spanish Mixed Committee on New Drugs Assessment (MCNDA)
The information available on the efficiency and safety of new medicines is limited and almost exclusively comes from the clinical trials carried out for authorization purposes. These trials may guarantee the quality, safety and efficiency of the products but do not evaluate their role in therapeutics in comparison with other available alternatives. To reach this aim there hould be objective and independent information available about new medicines from evidence-based drug evaluations carried out with a systematic, rigorous and transparent methodology.
- Mixed Committee on New Drugs Assessment.